AlecOr-backed work advanced a mechanism-based Parkinson’s strategy: Cerevance reported in a phase 3 trial that solengepras reduced daily “off” time in Parkinson’s patients, positioning the pill as a dopamine-independent add-on option. The company is now expected to discuss potential approval with regulators. In a separate development deal, Genentech signed an $1.27 billion deal for Alector’s preclinical AL050, an enzyme replacement therapy targeting glucocerebrosidase deficiency in GBA1 mutation carriers—paired with a brain-carrier technology designed to cross the blood-brain barrier. The agreement structure includes an upfront payment and milestone payments. These updates highlight parallel momentum in Parkinson’s drug development—one moving through late-stage efficacy readouts and another securing major partnering capital for enzyme delivery and neurodegeneration targets.